Internal Reference Number: FOI_6507
Date Request Received: 08/03/2022 00:00:00
Date Request Replied To: 23/03/2022 00:00:00
This response was sent via: By Email
Request Summary: Use of targeted therapies in blood-related cancers
Request Category: Companies
| Question Number 1: How many patients have you treated in the last 3 months for Multiple Myeloma? | |
| Answer To Question 1: Please be advised that this response is based off of figure for the last of SACT, and that single agent steroids won't be included in these results. As of the date of sending we have treated 52 patients in the last 3 months for Multiple Myeloma. | |
| Question Number 2: How many have received the following treatments? See attachment to complete | |
| Answer To Question 2: Below is breakdown of the treatments issued, any treatment not listed should be considered as 0 of this treatment being used in the previous 3 months Bortezomib, thalidomide and dexamethasone <5 VCD <5 Lenalidomide monotherapy 13 CTD <5 Bortezomib monotherapy <5 Carfilzomib/dexamethasone <5 DVD <5 Daratumumab, lenalidomide, dexamethasone <5 Daratumumab monotherapy 9 IsaPd <5 IRD 17 Panobinostat, bortezomib, dexamethasone <5 Any other systemic anti-cancer treatment To accompany this answer to question 2 please also see the documents listed below:  FOI 6507.docx | |
| Please see Attachments: | |
| To return to the list of all the FOI requests please click here | |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of ¾¨Ó㴫ý Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
